iNHL
Showing 1 - 25 of 51
Indolent Lymphoma, Low-dose Radiotherapy Trial in Beijing (Low-dose radiotherapy)
Recruiting
- Indolent Lymphoma
- Low-dose Radiotherapy
- Low-dose radiotherapy
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Sep 13, 2022
Cough Trial in Hamilton (Salbutamol 5mg/mL, Sodium Chloride 0.9% Inhl 3Ml)
Completed
- Cough
- Salbutamol 5mg/mL
- Sodium Chloride 0.9% Inhl 3Ml
-
Hamilton, Ontario, Canada
- +1 more
Jun 13, 2022
Obinutuzumab in Chinese Real-world Patients With iNHL
Not yet recruiting
- Lymphomas Non-Hodgkin's B-Cell
-
Changzhou, Jiangsu, China
- +24 more
Jul 23, 2023
Lymphoma, Non-Hodgkin Trial in Beijing (Copanlisib (Aliqopa, BAY80-6946))
Completed
- Lymphoma, Non-Hodgkin
- Copanlisib (Aliqopa, BAY80-6946)
-
Beijing, ChinaBeijing Cancer Hospital
May 17, 2021
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin Trial in France, Italy, Netherlands (Obinutuzumab, CC-122)
Active, not recruiting
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
-
Borddeaux Cedex, France
- +9 more
Nov 11, 2022
Chronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma Trial in Aichi, Miyagi, Tokyo (Idelalisib)
Completed
- Chronic Lymphocytic Leukemia
- +5 more
-
Aichi, Japan
- +2 more
Feb 24, 2021
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in
Suspended
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +7 more
- Venetoclax
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma Trial in United States (Rituximab, ALT-803)
Terminated
- Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
- Rituximab
- ALT-803
-
Minneapolis, Minnesota
- +3 more
Feb 11, 2021
Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of
Active, not recruiting
- Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
- Copanlisib (BAY80-6946)
-
Multiple Locations, TaiwanMany Locations
Jan 31, 2023
Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Trial in United States (TAK-007, Chemotherapy Agents)
Recruiting
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- TAK-007
- Chemotherapy Agents
-
Birmingham, Alabama
- +18 more
Aug 17, 2022
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (BAY80-6946), Placebo, Rituximab)
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (BAY80-6946)
- +7 more
-
Chandler, Arizona
- +199 more
Jan 31, 2023
Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell Trial in Worldwide (pembrolizumab, Favezelimab)
Recruiting
- Hodgkin Disease
- +2 more
- pembrolizumab
- Favezelimab
-
Gilbert, Arizona
- +24 more
Aug 18, 2022
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Zandelisib, Rituximab, Bendamustine)
Recruiting
- Follicular Lymphoma (FL)
- +2 more
- Zandelisib
- +3 more
-
Tucson, Arizona
- +134 more
Jul 27, 2022
Asthma, Cough Trial in Hamilton (Mannitol, Salbutamol 5mg/mL, Sodium Chloride 0.9% Inhl 3Ml)
Completed
- Asthma
- Cough
- Mannitol
- +2 more
-
Hamilton, Ontario, CanadaMcMaster University
Feb 12, 2020
Inert Non Hodgkin's Lymphoma Trial in Beijing (IBI376, Rituximab)
Recruiting
- Inert Non Hodgkin's Lymphoma
- IBI376
- Rituximab
-
Beijing, ChinaBiotherapeutic Department, Chinese PLA General Hospital
Feb 19, 2022
Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia Trial in Bergamo (Blinatumomab Expanded T-cells (BET))
Active, not recruiting
- Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
- Blinatumomab Expanded T-cells (BET)
-
Bergamo, ItalyASST - Papa Giovanni XXIII
Dec 22, 2021
Advanced Solid Tumor and Lymphoma Malignancies Trial in Worldwide (TAK-659)
Completed
- Advanced Solid Tumor and Lymphoma Malignancies
-
Sarasota, Florida
- +14 more
Jul 15, 2021
Indolent Non-hodgkin Lymphoma Trial in Worldwide (Duvelisib)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
Washington, District of Columbia
- +39 more
May 17, 2021
Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma Trial in United States (Duvelisib, Placebo,
Withdrawn
- Indolent Non-Hodgkin's Lymphoma
- +3 more
- Duvelisib
- +3 more
-
Plainville, Connecticut
- +6 more
Mar 15, 2021